<table width="80%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1: Clinically Significant Drug Interactions with Morphine Sulfate Oral Solution</caption>
<col width="30%"></col>
<col></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions</content>
<content stylecode="italics">(<linkhtml href="#redlines-PI.doc#_5.5_Risks_from">5.5</linkhtml>)]</content>.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Examples:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome<content stylecode="italics">.</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.  Discontinue Morphine Sulfate Oral Solution if serotonin syndrome is suspected.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Examples:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),  triptans,  5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_cef138f5-ff6e-4e75-b989-634e66d79b99">5.3</linkhtml>, <linkhtml href="#LINK_ea44403e-f3ce-48ab-be78-0a7155d8b4d5">5.7</linkhtml>)]</content>. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Do not use Morphine Sulfate Oral Solution in patients taking MAOIs or within 14 days of stopping such treatment. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">phenelzine, tranylcypromine, linezolid</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">  <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> May reduce the analgesic effect of Morphine Sulfate Oral Solution and/or precipitate withdrawal symptoms.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> Avoid concomitant use.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Examples:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> butorphanol, nalbuphine, pentazocine, buprenorphine,</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Oral Solution and/or the muscle relaxant as necessary.</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Cimetidine </content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">The concomitant use of morphine and cimetidine has been reported to precipitate apnea, confusion, and muscle twitching in an isolated report.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">  <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients for increased respiratory and CNS depression when Morphine Sulfate Oral Solution is used concomitantly with cimetidine.</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">  <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">Anticholinergic Drugs</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">  <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients for signs of urinary retention or reduced gastric motility when Morphine Sulfate Oral Solution is used concomitantly with anticholinergic drugs.</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="bold">P-Glycoprotein (P-gp) Inhibitors</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Oral Solution and/or the P-gp inhibitor as necessary.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">quinidine, verapamil </td>
</tr>
</tbody>
</table>